ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
复制标题
DOI：
10.1016/s0140-6736(89)91141-0
复制
发表时间：
1989-01
期刊：
影响因子：
--
通讯作者：
T. Fornander;B. Cedermark;A. Mattsson;L. Skoog;T. Theve;J. Askergren;LabsE. Rutqvist;U. Glas;C. Silfverswärd;A. Somell;N. Wilking;M. Hjalmar
中科院分区：
文献类型：
--
作者：
T. Fornander;B. Cedermark;A. Mattsson;L. Skoog;T. Theve;J. Askergren;LabsE. Rutqvist;U. Glas;C. Silfverswärd;A. Somell;N. Wilking;M. Hjalmar
对1846名绝经后患者的新原发癌症发生率进行了研究，这些患者包括在一项随机试验中，他莫昔芬作为早期乳腺癌初次手术的辅助手段。中位随访时间为4.5年(0.5~10.5年)。他莫昔芬组(n=57)新发癌症的数量与对照组(n=70)无显著差异。然而，在他莫昔芬患者中，第二次乳腺癌的发生率低于对照组，而子宫内膜癌的发生率高于对照组。子宫内膜癌的增加可能与他莫昔芬的激动型雌激素效应有关，并且在那些治疗超过2年的患者中最为明显。
The frequency of new primary cancers was studied in 1846 postmenopausal patients included in a randomised trial of tamoxifen as an adjunct to primary surgery for early breast cancer. The median follow-up was 4·5 years (range 0·5-10·5 years). The number of new cancers in the tamoxifen group (n = 57) did not differ significantly from that in the control group (n=70). However, in tamoxifen patients second breast cancers occurred less often and endometrial cancer occurred more often than in the controls. The increase in endometrial cancers was probably related to the agonistic oestrogenic effects of tamoxifen and was most pronounced in those treated for over 2 years.